Boston, MA
Visit us at booth 713
Your lab, our tests
Empowering sample and data ownership with kitted solutions for your lab
Your tests, our lab
Compliment comprehensive in-house solution with guideline-drived send out tests
Closing the precision oncology gap
We create clarity for patients and their clinicians by removing barriers to precision oncology testing in order to make timely, personalized cancer treatments a reality for all.
Democratizing access to CGP with distributed kits
Delivering rapid insights to guide personalized treatment decisions
Elevating the standard of care for all
Connect with us at AMP!
Visit booth 713
Meet with members of Labcorp Oncology
Attend our workshop and innovation spotlight theater
Wednesday, November 12, 2025 | 11:00 AM – 11:50 AM | Location: 158, Level 1
Workshop: Expanding access to CGP: Bridging gaps and facilitating integration to reach more patients
Comprehensive Genomic Profiling (CGP) is a cornerstone of precision medicine, yet access remains uneven across patient populations, particularly in underserved areas. This workshop will feature a panel of subject matter experts from across the industry who will share insights on expanding accessibility to CGP testing. We will explore the real-world barriers that limit access to comprehensive genomic profiling - such as geographic disparities, gaps in infrastructure, and the cost of testing. The session will also highlight emerging solutions such as integration with electronic medical records (EMRs) and adoption of scalable technologies to facilitate integration of this testing practice into routine clinical workflows. Attendees will gain insight into tools and digital strategies that help bridge testing gaps and enable broader, more equitable access to increased genomic insights that may help improve outcomes.
Friday, November 14, 2025 | 3:00 PM – 3:30 PM | Exhibit hall, stage 2
Spotlight theater: Decoding the HRD puzzle: Enhancing precision oncology through expanded genomic profiling
Speaker: Dr. Kyle C. Strickland, M.D., Ph.D., Director of Medical Affairs, Labcorp
This session spotlights the latest enhancement to OmniSeq® INSIGHT—now reporting the genomic instability score (GIS)and homologous recombination deficiency (HRD) status, key biomarkers in epithelial ovarian, fallopian tube and primary peritoneal cancers. We’ll explore the therapeutic value of HRD assessment and its clinical relevance for pathologists and molecular-diagnostics laboratories. The presentation also examines the integration of germline and somatic testing to identify hereditary cancer syndromes and guide patient management. Together, these advancements deliver a more comprehensive molecular profile, enabling precision oncology approaches in gynecologic cancers.
Spotlight on science
Review our list of posters that will be presented at AMP
| Session Date and Time | Abstract # | Poster # | Title | Presenting author | Category |
|---|---|---|---|---|---|
| Friday, November 14th | |||||
| Friday, November 14th from 9:15am – 10:15am Eastern | 2168278 | TT076 | Single Digit Parts per Million Detection of Molecular Residual Disease Through Integrated Tumor-Informed Whole-Genome Sequencing Analysis | Stephen Higgins | Technical Topics |
| Friday, November 14th from 9:15am – 10:15am Eastern | 2169825 | ST092 | Labcorp Plasma Complete Real-World Evidence (RWE) Analysis to Demonstrate Clinical Utility and Actionability in Cancer Patients | Laine Morris | Solid Tumors |
| Friday, November 14th from 9:15am – 10:15am Eastern | 2167815 | ST076 | Concordance Analysis of Liquid Biopsy-based Tumor Variant Detection Between a Centralized Specialty Laboratory and the PGDx elio™ plasma focus Dx Kitted Solution | Tonya Watkins | Solid Tumors |
| Friday, November 14th from 9:15am – 10:15am Eastern | 2169469 | ST100 | Revealing new utilities of MRD Assays in Patients with Unresectable Pancreatic Cancer | Jacquelyn Reuther | Solid Tumors |
| Saturday, November 15th | |||||
| Saturday, November 15th from 9:15am – 10:15am Eastern | 2168615 | ST145 | Artificial Intelligence-Powered Spatial Analysis Reveals Distinct Tumor-Immune Microenvironments Associated with MET Mutations in Non-Small Cell Lung Cancer | Zachary Wallen | Solid Tumors |
| Saturday, November 15th from 9:15am – 10:15am Eastern | 2168576 | ST169 | Targeted Immune Gene Expression Profiling of FGFR-Altered Bladder Cancer Reveals a Distinct Immunological Landscape from FGFR Wildtype Tumors | Zachary Wallen | Solid Tumors |
| Saturday, November 15th from 9:15am – 10:15am Eastern | 2169695 | ST147 | Clinical characterization and functional annotation of solid tumor gene fusions using the DRAGEN analysis pipeline | Maria-Fernanda Senosain | Solid Tumors |
| Saturday, November 15th from 9:15am – 10:15am Eastern | TT033 | TT033 | Automation of PGDx elio™ tissue complete on the Beckman Coulter Biomek NGeniuS System | Anita Patel | Technical Topics |
| Saturday, November 15th from 9:15am – 10:15am Eastern | 2169412 | ST153 | Immune Gene Expression Patterns in Molecular Subtypes of Endometrial Carcinoma | Kyle Strickland | Solid Tumors |
| Saturday, November 15th from 9:15am – 10:15am Eastern | 2169626 | H003 | Cytogenetic Advances in NHL Diagnosis by Leveraging Hi-C Sequencing | External author | Solid Tumors |
| Saturday, November 15th from 9:15am – 10:15am Eastern | 2169899 | ST075 | Comprehensive Genomic Profiling Reveals Subtle Microsatellite Instability in Endometrial Carcinoma | External author | Solid Tumors |